Evidence mapPaperPMID 31673705Full record

ArticleAmerican journal of epidemiology2020

Inflammatory Markers and Incidence of Hospitalization With Infection in Chronic Kidney Disease.

Junichi Ishigami, Jonathan Taliercio, Harold I Feldman, Anand Srivastava, Raymond Townsend, Debbie L Cohen, Edward Horwitz, Panduranga Rao, Jeanne Charleston, Jeffrey C Fink and 8 more

Abstract read
In one paragraph

Article in American journal of epidemiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Junichi Ishigami
Jonathan Taliercio
Harold I Feldman
Anand Srivastava
Raymond Townsend
Debbie L Cohen
Edward Horwitz
Panduranga Rao
Jeanne Charleston
Jeffrey C Fink
Ana C Ricardo
James Sondheimer
Teresa K Chen
Myles Wolf
Tamara Isakova
Lawrence J Appel
Kunihiro Matsushita
CRIC Study Investigators

Funding

Scientific and Data Coordinating Center(SDCC) for the P*U01DK060990 · UNIVERSITY OF PENNSYLVANIA · 2001 to 2005
$12.7M
Zonulin Antibodies in Intestinal Permeabilitiy in IDDMM01RR016500 · UNIVERSITY OF MARYLAND BALTIMORE · 2002 to 2005
$10.6M
CARDIOVASCULAR EPIDEMIOLOGY INSTITUTIONAL TRAININGT32HL007024 · JOHNS HOPKINS UNIVERSITY · 1985 to 2025
$3.7M
Study of the Care and Outcomes of REnal InsufficiencyU01DK060902 · KAISER FOUNDATION RESEARCH INSTITUTE · 2001 to 2025
$3.4M
Limited Competition for the Continuation of the Chronic Renal Insufficiency Cohort (CRIC) Hopkins Clinical CenterU01DK061022 · JOHNS HOPKINS UNIVERSITY · 2001 to 2025
$3.3M
Prospective Cohort Study of Chronic Renal InsufficiencyU01DK061028 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2001 to 2025
$3.3M
Proposal for a Chicago-CRIC Clinical CenterU01DK060980 · UNIVERSITY OF ILLINOIS AT CHICAGO · 2001 to 2025
$3.2M
Prospective Renal Insufficiency Cohort Evaluation:PRICEU01DK060984 · UNIVERSITY OF PENNSYLVANIA · 2001 to 2025
$3.0M
Cohort Study of Chronic Renal InsufficiencyU01DK061021 · CASE WESTERN RESERVE UNIVERSITY · 2001 to 2025
$2.9M
Tulane Clinical Center for Chronic Renal Insufficiency Cohort StudyU01DK060963 · TULANE UNIVERSITY OF LOUISIANA · 2001 to 2025
$2.7M
Tulane COBRE for Clinical and Translational Research in Cardiometabolic DiseasesP20GM109036 · TULANE UNIVERSITY OF LOUISIANA · 2025 to 2025
$2.2M
Continuation of the Chronic Renal Insufficiency Cohort (CRIC)U24DK060990 · UNIVERSITY OF PENNSYLVANIA · 2025 to 2025
$1.1M
NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1 TR000424NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR001422NCATS NIH HHS UL1 TR002003NCATS NIH HHS UL1 TR002240NCATS NIH HHS UL1 TR002548NCRR NIH HHS M01 RR016500NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR029879NHLBI NIH HHS T32 HL007024NIDDK NIH HHS R01 DK139225NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01 DK060963NIDDK NIH HHS U01 DK060980NIDDK NIH HHS U01 DK060984NIDDK NIH HHS U01 DK060990NIDDK NIH HHS U01 DK061021NIDDK NIH HHS U01 DK061022NIDDK NIH HHS U01 DK061028NIDDK NIH HHS U24 DK060990NIGMS NIH HHS P20 GM109036
6 · The paper itself

Abstract

Persons with chronic kidney disease (CKD) are at high risk of infection. While low-grade inflammation could impair immune response, it is unknown whether inflammatory markers are associated with infection risk in this clinical population. Using 2003-2013 data from the Chronic Renal Insufficiency Cohort Study (3,597 participants with CKD), we assessed the association of baseline plasma levels of 4 inflammatory markers (interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-1 receptor antagonist (IL-1RA), and transforming growth factor-β (TGF-β)) with incident hospitalization with major infection (pneumonia, urinary tract infection, cellulitis and osteomyelitis, and bacteremia and sepsis). During follow-up (median 7.5 years), 36% (n = 1,290) had incident hospitalization with major infection. In multivariable Cox analyses with each inflammatory marker modeled as a restricted cubic spline, higher levels of IL-6 and TNF-α were monotonically associated with increased risk of hospitalization with major infection (for 95th vs. 5th percentile, hazard ratio = 2.11 (95% confidence interval: 1.68, 2.66) for IL-6 and 1.88 (95% confidence interval: 1.51, 2.33) for TNF-α), while corresponding associations for IL-1RA or TGF-β were nonsignificant. Thus, higher plasma levels of IL-6 and TNF-α, but not IL-1RA or TGF-β, were significantly associated with increased risk of hospitalization with major infection. Future studies should investigate whether inflammatory pathways that involve IL-6 and TNF-α increase susceptibility to infection among individuals with CKD.

Indexed as

AdultAgedBiomarkersDisease SusceptibilityFemaleHospitalizationHumansIncidenceInfectionsInflammationInterleukin 1 Receptor Antagonist ProteinInterleukin-6MaleMiddle AgedProspective StudiesRenal Insufficiency, ChronicBiomarkersInterleukin 1 Receptor Antagonist ProteinInterleukin-6Transforming Growth Factor betaTumor Necrosis Factor-alphachronic kidney diseasechronic renal insufficiencyinfectioninfectious diseaseinterleukin-1 receptor antagonistinterleukin-6transforming growth factor-βtumor necrosis factor-α

Identifiers

PMID31673705
PMCPMC7306687

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.